You are on page 1of 1

Umbralisib in Patients with CLL who are Intolerant to Prior BTK or PI3K-delta Inhibitor

Therapy

- CLL (chronic lymphocytic leukemia)


- Most common symptoms: fatigue, swollen lymph nodes, infection, fever
- Treatment:
- BTK inhibitors (ex: ibrutinib)-1st line therapy
- ADE: fatigue, diarrhea, bruising
- NCCN: CLL
- PI3K inhibitors (ex: duvelisib, idelalisib)-2nd line therapy
- ADE: diarrhea, neutropenia, rash, hypertriglyceridemia, hyperglycemia,
fever
- NCCN: relapsed CLL

You might also like